Chemicals · NSE: AARTIIND
Aarti Industries
Q2 FY27 earnings call · Guided by management
Call held 2 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹17,552Cr
- P/E
- 29.6×
- 1Y return
- +21.86%
- From 52W high
- −12.3%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 3,668 | 2,100 | +74.7% | 2,387 | +53.7% |
| EBITDA | 411 | 291 | +41.0% | 382 | +7.5% |
| EBITDA margin | 11.2% | 13.9% | -268 bps | 16.0% | -481 bps |
| One-off items | — | 22 | — | 2 | — |
| PBTProfit before tax | 204 | 94 | +118.6% | 180 | +13.5% |
| Net profit | 168 | 106 | +58.8% | 155 | +8.6% |
| EPS (₹) | 4.65 | 2.91 | +59.8% | 4.26 | +9.2% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q1 FY27 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.
Guidance
Guidance for next year to be given closer to the end of the financial year
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
Guidance for next year to be given closer to the end of the financial year
“But broadly, we expect the current momentum to continue and on the basis of that, we will come up with appropriate guidance for the next year, closer to the end of the financial year.”
Zone IV: Aim for Zone IV to add to EBITDA in FY28
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
Zone IV: Aim for Zone IV to add to EBITDA in FY28
“The aspiration is to get Zone IV additive to EBITDA in FY28 itself and that is the current plan.”
Management says three levers give line of sight to its guided EBITDA range
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 19
Management says three levers give line of sight to its guided EBITDA range
“So across the three levers is what gives us line of sight to achieve the range that we had mentioned in our guidance.”
More figures from the call
“From a margin standpoint, in the first 18 months, our target is to achieve INR250 crore to INR350-odd crore of bottom line from Zone IV, and I think we continue to push for that aspiration.”
“In Fuel Additives, the capacity utilization remained strong in Q2 following our expansion from 290 KTPA to 360 KTPA in the first quarter of 2026.”
“For DCB, the capacity debottlenecking to 140 KTPA remains aligned with downstream PDCB demand.”
“Commercial production is expected to commence soon, with steady-state revenue projected at Rs. 300-400 crore.”
“Usually, it is around 25% to 30% of our business that comes through some of these long-term partnerships. We hope the share of that will go up going forward as we do more and more such partnerships.”
“We have a pipeline of 50 to 60 different initiatives, typically focused on yield, energy, throughput quality, all four levers and including fixed cost optimization.”
In short
- 01Q2 FY27 revenue was Rs 3,887 crore, up 73%; EBITDA was Rs 418 crore, up 44%.
- 02Net debt rose to over Rs 4,650 crore on higher raw material prices; up to Rs 1,000 crore fund raise approved to deleverage.
- 03Management says it has line of sight to its FY28 EBITDA guidance range; next year's guidance to come near year end.
- 04Zone IV Phase I commissioned on 7 September 2026; remaining chemistry blocks expected within FY27, ramp-up through FY28.
- 05Zone IV targeted at Rs 250-350 crore bottom line in first 18 months and to add to EBITDA in FY28.
- 06New 10+ year supply contract signed with revenue potential of about Rs 1,500 crore; operations targeted for FY29.
- 07FY27 capex planned at Rs 700-800 crore; NCB expansion would be debottlenecking, not greenfield.
- 08Energy expected to settle at 30% to 40% of the portfolio in the midterm.
Capex
Zone IV: Zone IV Phase I commissioned on September 7, 2026
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
Zone IV: Zone IV Phase I commissioned on September 7, 2026
“The Phase I of Zone IV was officially commissioned on September 7, 2026.”
Zone IV: Calcium Chloride, PEDA and part of multipurpose plant operational, under stabilisation
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
Zone IV: Calcium Chloride, PEDA and part of multipurpose plant operational, under stabilisation
“The Calcium Chloride unit, the PEDA (2-Phenyl Ethyl Diethyl Aniline) plant, and a section of the Multipurpose Plant (MPP) are now operational and are undergoing stabilization.”
Zone IV: Remaining 4 Zone IV chemistry blocks expected online within this financial year
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
Zone IV: Remaining 4 Zone IV chemistry blocks expected online within this financial year
“The remaining 4 chemistry blocks are expected to come online within this financial year, positioning Zone IV as a strategic growth driver for next 18-24 months.”
Zone IV: Most CWIP should be capitalised by 31 March 2027
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 9
Zone IV: Most CWIP should be capitalised by 31 March 2027
“So by 31st March 2027, most of it should get capitalized.”
NCB: NCB expansion to be debottlenecking, not greenfield; capital intensity not much higher
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 13
NCB: NCB expansion to be debottlenecking, not greenfield; capital intensity not much higher
“Even in NCB, we are looking at a debottlenecking capex and not necessarily a greenfield capex. So from that point of view, capital intensity would not be significantly higher”
Capacity
NCB: NCB utilisation elevated; capacity expansion under evaluation
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
NCB: NCB utilisation elevated; capacity expansion under evaluation
“With current NCB asset utilization remaining elevated, the capacity expansion initiatives are under evaluation by the management team.”
MMA: MMA ran at almost full capacity in Q2
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 9
MMA: MMA ran at almost full capacity in Q2
“I think in the second quarter, we ran almost at full capacity.”
Zone IV: Calcium Chloride plant above design capacity within three months
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
Zone IV: Calcium Chloride plant above design capacity within three months
“The Calcium Chloride plant that we commissioned has achieved more than design capacity within first three months of operation.”
Zone IV: PEDA plant reached design capacity within two months
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
Zone IV: PEDA plant reached design capacity within two months
“The PEDA plant that we commissioned is able to achieve its design capacity and design norms within the first two months of its operation.”
Energy: Energy: near-term aim is to stabilise at current capacity before weighing expansion
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 19
Energy: Energy: near-term aim is to stabilise at current capacity before weighing expansion
“So for the time being, our objective is to stabilize at this capacity and as I mentioned earlier, stabilize our integrated value chain presence, which brings more robustness, more stability to the earnings profile of these value chains. Once we have achieved that, then we could go back and potentially evaluate further expansion.”
Order book
10+ year supply agreement with global specialty chemical major, revenue potential ~Rs 1,500 crore
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
10+ year supply agreement with global specialty chemical major, revenue potential ~Rs 1,500 crore
“On October 13, 2026, we also entered into a dedicated 10+ year manufacturing and supply agreement with a global specialty chemical major, representing a revenue potential of ~Rs. 1,500 crore.”
Two specialty contracts run to late 2030s-2040; AgChem contract to 2029-2030
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
Two specialty contracts run to late 2030s-2040; AgChem contract to 2029-2030
“I think if I am not wrong, we are expecting this to run in late 2030s up to 2040, some of them versus the AgChem contract will last till 2029, 2030 kind of a time frame.”
Specialty chemicals: Specialty contracts structured around margins; performing as per expectations
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
Specialty chemicals: Specialty contracts structured around margins; performing as per expectations
“But given the nature of our commercial arrangement, what is more important is the bottom line because the commercials are structured around margins and not necessarily around top line and that continues to perform as per expectations.”
Specialty chemicals: Advanced polymer demand for EVs and electronics picked up; contract volumes up
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
Specialty chemicals: Advanced polymer demand for EVs and electronics picked up; contract volumes up
“The demand portfolio for the advanced polymer going into EVs and electronics’ space has actually picked up. So the volumes there have gone up.”
No discontinuation expected from the three long-term contracts
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
No discontinuation expected from the three long-term contracts
“So there is no reason that we expect discontinuation of business performance from any of these contracts.”
Segments
Agrochemicals: Agrochemicals second half may reflect weaker domestic monsoon
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
Agrochemicals: Agrochemicals second half may reflect weaker domestic monsoon
“The second half might reflect the impact of weaker monsoon in the domestic market.”
Polymers & Additives: PDA softness dragged Q2; traction expected to resume in Q3 FY27 on DCB demand
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
Polymers & Additives: PDA softness dragged Q2; traction expected to resume in Q3 FY27 on DCB demand
“While softness in the PDA chain created a short-term drag on our Q2 FY27 performance, we expect traction to resume in Q3 FY27, underpinned by accelerating DCB demand.”
PDA: Re-evaluating use of PDA assets; no volume growth pursued there for now
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
PDA: Re-evaluating use of PDA assets; no volume growth pursued there for now
“PDA is one chain where we are reevaluating how we should utilize those assets in the most efficient manner. But there, at this point in time, we are not pursuing strategic growth from a volume standpoint”
Ethylation: Ethylation volume growth expected to continue
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
Ethylation: Ethylation volume growth expected to continue
“with our multiproduct strategy, including MEA, DEA and some of the other specialty ethylation/propylation-based chemistries, we expect the volume growth to continue there as well.”
Pharma: Pharma volumes grew significantly; NCB chain expansion being considered
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 8
Pharma: Pharma volumes grew significantly; NCB chain expansion being considered
“I think that is one sector where we have also significantly grown in terms of volumes, which is reflected in our NCB chain utilization levels and we are also considering potential expansion possibilities for that value chain.”
Demand
NCB: NCB demand very strong; capacity expansion considered on customer requests
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
NCB: NCB demand very strong; capacity expansion considered on customer requests
“The NCB, which is predominantly a domestic market, the demand trends are very strong. We are actually considering capacity expansion being pushed by requests from our customers.”
DCB: DCB first half usually softer, second half strong as US flows start
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 6
DCB: DCB first half usually softer, second half strong as US flows start
“On DCB side, the first half is usually a softer, second half is very strong as the U.S. flows kick in.”
Energy: Energy pull-up in Q2 linked to strong refining margins and gasoline-naphtha cracks
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
Energy: Energy pull-up in Q2 linked to strong refining margins and gasoline-naphtha cracks
“We have seen a huge pull-up from the energy portfolio in the second quarter specifically, which was linked to extremely strong refining margin and gasoline- naphtha cracks.”
Energy: Domestic demand for Fuel Additives picking up
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
Energy: Domestic demand for Fuel Additives picking up
“Second, we have domestic demand picking up for the Fuel Additives portfolio in the market and in some cases, some of the exported volume has also been bought in the domestic market.”
Energy: Gasoline-naphtha crack was $20-plus per barrel last quarter
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 11
Energy: Gasoline-naphtha crack was $20-plus per barrel last quarter
“The gasoline-naphtha crack, it was very robust. It was $20-plus per barrel, if I look at last quarter.”
Margins and costs
Almost all raw materials rose in price; Sulphur up over 5-6x
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
Almost all raw materials rose in price; Sulphur up over 5-6x
“Almost all of our raw materials saw significant price increase, while RMs such as Sulphur saw prices surge by over 5-6x”
Pharma & Fluoro Products: Fluoro products margins remain under pressure
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
Pharma & Fluoro Products: Fluoro products margins remain under pressure
“The Fluoro products’ margins continue to remain under pressure.”
NCB: NCB spreads above original assumption, offset by Zone IV delay
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
NCB: NCB spreads above original assumption, offset by Zone IV delay
“So there is definitely an upside in the NCB chain that we are seeing compared to our assumption. At the same time, we are running a bit delayed on Zone IV, right.”
Possible margin upside if China anti-involution and VAT rebate removal spread
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
Possible margin upside if China anti-involution and VAT rebate removal spread
“If there is a further improvement in margin spread due to China's current stand linked to anti-involution and removal of, VAT rebate removal if that sort of gets passed on to multiple other value chains, we could see an upside in the margins”
Agrochemicals: Agrochemical quarterly contracts pass through prices with a one-quarter lag
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
Agrochemicals: Agrochemical quarterly contracts pass through prices with a one-quarter lag
“In many of the segments, for example, in Agrochemicals, we have quarterly contracts, right. So there is a lag of quarter when it comes to pass-through of the pricing.”
Debt and working capital
Net debt rose to over Rs 4,650 crore as raw material prices stretched working capital
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Net debt rose to over Rs 4,650 crore as raw material prices stretched working capital
“Elevated RM prices have also stretched our working capital requirements over the past two quarters, pushing our net debt to over Rs. 4,650 crore and leading to higher finance costs.”
Working capital optimised to 55 to 60 days
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 8
Working capital optimised to 55 to 60 days
“But in terms of days, we have practically optimized to 55 to 60 days of working capital, which is the optimum level at which we could operate.”
Rs 800 crore to Rs 1,000 crore of inventory on the water at any time
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 10
Rs 800 crore to Rs 1,000 crore of inventory on the water at any time
“we roughly have anywhere between INR 800 crore to INR 1,000 crore worth of inventory on the waters”
Fund raising
Board approved enabling resolution to raise up to Rs 1,000 crore
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Board approved enabling resolution to raise up to Rs 1,000 crore
“the Board, on October 1, 2026, approved an enabling resolution to raise up to Rs. 1,000 crore”
Shareholders approved the fund raise resolution at EGM on 31 October 2026
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Shareholders approved the fund raise resolution at EGM on 31 October 2026
“The said enabling resolution has been approved by the Shareholders in the EGM held on 31st October 2026”
Acquisitions and new business
Energy: Several new energy solutions expected to launch over next 12 to 24 months
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 3
Energy: Several new energy solutions expected to launch over next 12 to 24 months
“Leveraging our bulk shipment capabilities and robust R&D pipeline, we anticipate launching of several new solutions over the next 12 to 24 months.”
Aarti Circularity: Aarti Circularity plastic recycling JV execution on track
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 5
Aarti Circularity: Aarti Circularity plastic recycling JV execution on track
“Project execution for Aarti Circularity (Plastic Recycling JV) remains on track.”
Evaluating customer-backed projects in personal care, flavours, batteries, defence
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 15
Evaluating customer-backed projects in personal care, flavours, batteries, defence
“Right now, as we speak, we are looking at strategic projects backed up by customers' demand in areas like personal care, for example, flavors and fragrances, batteries, in defense.”
New contract a start; more projects and capacity expansion hoped with client
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 16
New contract a start; more projects and capacity expansion hoped with client
“I think this is just a start of relationship with a new client. We hope to do many more projects, including expanding capacity under the existing contracts”
Only signed deals announced; other application partnerships still in talks
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 18
Only signed deals announced; other application partnerships still in talks
“As of now, whatever has got confirmed and signed is what we have communicated to the market and rest of them remains in the conversation stage.”
One-offs
Q1 inventory and FX gain was about Rs 50-60 crore; nothing significant in Q2
Chetan Gandhi · Chief Financial Officer · Q&A · p. 8
Q1 inventory and FX gain was about Rs 50-60 crore; nothing significant in Q2
“In first quarter, we had indicated that the inventory and FX was roughly around INR 50 - 60 crore as a combined number.”
Provision taken in the quarter is for goods in transit
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 16
Provision taken in the quarter is for goods in transit
“Yes, it is for goods in transit.”
Risks
Q3 domestic raw material availability good; imported raw materials may see supply gaps
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Q3 domestic raw material availability good; imported raw materials may see supply gaps
“early indications for Q3 point indicates for the domestic RM, we will continue to have good availability and visibility while for imported RM, there could be supply chain gaps that we will have to mitigate.”
Zone IV fixed costs from Q4 and a crude price correction named as risks
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 7
Zone IV fixed costs from Q4 and a crude price correction named as risks
“There might be certain issues around Zone IV commissioning and the fixed cost associated with that coming into the P&L around Q4 and if there is a major correction in the global crude oil pricing scenario and if that has an impact potentially on some of the inventory, these are the two issues that we have to watch out for.”
Inventory loss risk managed by forward booking, cannot be fully eliminated
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 8
Inventory loss risk managed by forward booking, cannot be fully eliminated
“Wherever possible, we are trying to do forward booking of the contracts to ensure that our exposure gets minimized to the best extent possible. But irrespective of everything that we do, the risk cannot be fully eliminated.”
PDA: PDA hit by Chinese overcapacity and dumping
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 11
PDA: PDA hit by Chinese overcapacity and dumping
“No, we see huge overcapacity and dumping by some of the Chinese players for this particular product in the global market.”
MMA: MMA competitors have added capacity; company still placing its volumes
Suyog Kotecha · Managing Director and Chief Executive Officer · Q&A · p. 14
MMA: MMA competitors have added capacity; company still placing its volumes
“Competition is there and some of them have ramped up the capacity. We have also ramped up our capacity. But we have also been able to place our capacity despite increasing competition.”
Other
Quarterly EBITDA crossed Rs 400 crore, reaching a record Rs 418 crore
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 2
Quarterly EBITDA crossed Rs 400 crore, reaching a record Rs 418 crore
“Most notably, our quarterly EBITDA surpassed the Rs. 400-crore threshold, reaching a record of Rs. 418 crore.”
Q2 FY27 revenue Rs 3,887 crore, up 73% year on year
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Q2 FY27 revenue Rs 3,887 crore, up 73% year on year
“Revenues in Q2 FY27 were at Rs. 3,887 crore, an increase of 73% over Q2 of last year.”
Q2 FY27 EBITDA up 44% year on year to Rs 418 crore
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Q2 FY27 EBITDA up 44% year on year to Rs 418 crore
“Q2 FY27 EBITDA increased by 44% year-on-year reaching Rs. 418 crore.”
Q2 FY27 PAT Rs 169 crore, up about 60% year on year
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Q2 FY27 PAT Rs 169 crore, up about 60% year on year
“PAT for the quarter increased to Rs. 169 crore with growth of about 60% over the same quarter in the previous year.”
Over 50 GenAI use cases executed last quarter
Suyog Kotecha · Managing Director and Chief Executive Officer · p. 4
Over 50 GenAI use cases executed last quarter
“our successful execution of over 50 GenAI use cases across our workspace last quarter alone.”
Sources
- Earnings call transcript, Q2 FY27 Filed 6 Nov 2026 · 20 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

